drugset / Trial / NCT03770026

Autologous Platelet-rich Plasma for Clomiphene Citrate-induced Thin Endometrium

NCT03770026

Phase 2/3 Completed 30 enrolled Benha University
Non-randomizedCrossoverSingle-blindTreatment

Summary

This is a prospective self-controlled clinical study. Women with clomiphene Citrate failure with thin endometrium less than 7 millimeters for at least 3 cycles will be selected (N = 30). Patients will receive 2 ovarian stimulation cycles with Clomiphene citrate (CC) 100 mg/ day for 5 days from cycle day 3. A control cycle (CC only cycle) woman will continue on CC alone plus cervical irrigation of cervix with 1 ml of 0.9% normal saline at cycle day 8 and 10 to assure patient-blinded method. The study group, the same will be done plus the intrauterine infusion of Autologous platelet-rich plasma (PRP) in 8th and 10th days of the cycle. In both groups, the endometrial thickness and Power Doppler evaluation of their endometrial and sub-endometrial blood flow will be measured on the day of Human Chorionic Gonadotropin (HCG) administration.

Timeline

Start
2018-01-01
Primary completion
2019-01-01
Completion
2020-01-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Clomiphene Other / unclassified 100 mg
Subject Platelet Rich Plasma Other / unclassified 0.5 ml Other
Subject Platelet Rich Plasma Other / unclassified 1 ml Other

Indications